Início › Linfoma de Burkitt › Nova York

Ensaios clínicos de Linfoma de Burkitt em Nova York

20 estudos para Linfoma de Burkitt estão buscando participantes em locais em Nova York.

Cidades em Nova York

Texto oficial do estudo (Inglês)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Albany Medical Center, Albany
Roswell Park Cancer Institute, Buffalo
NYU Langone Hospital - Long Island, Mineola
e mais 9

RecrutandoFase 2

366 Days – 46 Years · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Roswell Park Cancer Institute, Buffalo
Northwell Health/Center for Advanced Medicine, Lake Success
North Shore University Hospital, Manhasset
e mais 4

RecrutandoFase 3

Idades de 18 a 39 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Northwell Health/Center for Advanced Medicine, Lake Success
North Shore University Hospital, Manhasset
Long Island Jewish Medical Center, New Hyde Park
e mais 2

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Albany Medical Center, Albany
Roswell Park Cancer Institute, Buffalo
The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
e mais 7

RecrutandoFase 2

365 Days · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

David H. Koch Center for Cancer Care, New York
Montefiore Medical Center PRIME, The Bronx

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT07648264

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Memorial Sloan Kettering Cancer Center, New York

RecrutandoFase 3

Idades 1 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07223021

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Memorial Sloan Kettering Cancer Center ( Site 1010), New York
New York Medical College ( Site 1023), Valhalla

RecrutandoFase 1/2

6 Months – 25 Years · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT06395103

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

The Mount Sinai Hospital, New York

RecrutandoFase 1

Idades de 0 a 18 · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT06173518

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Columbia University Irving Medical Center/New York Presbyterian Hospital, New York

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT03666000

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Albany Medical Center, Albany
Maimonides Medical Center, Brooklyn
NYU Langone Hospital - Long Island, Mineola
e mais 7

RecrutandoFase 2

Idades de 1 a 30 · Todos os sexos · Atualizado em 1 de set. de 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Albany Medical Center, Albany
Maimonides Medical Center, Brooklyn
Roswell Park Cancer Institute, Buffalo
e mais 12

RecrutandoFase 3

365 Days – 25 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT03959085

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Research Site, New York

RecrutandoFase 1/2

Idades 12 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT06137118

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

New York Medical College, Valhalla

RecrutandoFase 1/2

Idades de 13 a 90 · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT06533579

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

New York Medical Center, Valhalla

RecrutandoFase 1/2

Idades de 12 a 70 · Todos os sexos · Atualizado em 15 de abr. de 2026 · NCT04491370

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Memorial Sloan Kettering Cancer Center, New York

RecrutandoFase 2

Idades de 18 a 54 · Todos os sexos · Atualizado em 17 de mar. de 2026 · NCT06918431

Study of SGR-1505 in Mature B-Cell Neoplasms

Roswell Park Comprehensive Cancer Center, Buffalo
Weill Cornell, New York
Montefiore Medical Center, The Bronx

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 13 de fev. de 2026 · NCT05544019

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Roswell Park Comprehensive Cancer Center, Buffalo

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 4 de nov. de 2025 · NCT03595917

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Roswell Park Comprehensive Cancer Center, Buffalo
Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

RecrutandoFase 1/2

Idades de 15 a 50 · Todos os sexos · Atualizado em 9 de set. de 2025 · NCT04150497

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

New York Medical College, Valhalla

RecrutandoFase 2

Idades de 3 a 31 · Todos os sexos · Atualizado em 8 de ago. de 2025 · NCT02393157

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

Roswell Park Cancer Institute, Buffalo

RecrutandoFase 2

Idades de 1 a 25 · Todos os sexos · Atualizado em 4 de mai. de 2025 · NCT03509961

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.